Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps

Sanofi and Regeneron’s Dupixent has been charging ahead since its initial approval in moderate-to-severe atopic dermatitis, later picking up a follow-up nod in moderate-to-severe asthma. Wednesday, the drug scored FDA approval for its third use: to treat adults with chronic rhinosinusitis with nasal polyps. Dupixent is the first biologic medicine approved for the condition, which obstructs sinuses and nasal passages.
Read more...

;